Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 22% Improvement Relative Risk Death/intubation 18% primary Ventilation 7% c19early.com/mf Lalau et al. Metformin for COVID-19 Prophylaxis Favors metformin Favors control
Lalau, 1,090 patient metformin prophylaxis PSM study: 22% lower mortality [p=0.16], 18% lower combined mortality/intubation [p=0.21], and 7% lower ventilation [p=0.72] https://c19p.org/lalau
copied to clipboard
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
Lalau et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216
10 Dec 2020    Source   PDF   Share   Tweet
Retrospective 2,449 hospitalized COVID-19 diabetes patients in France, 1,496 with existing metformin use, showing lower mortality with treatment. Statistical significance was reached in model 1 but not in models 2-4 which also adjust for HbA1c, eGFR, and diabetes duration, but have a lower number of patients. CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes).
risk of death, 22.2% lower, OR 0.78, p = 0.16, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
risk of death/intubation, 17.8% lower, OR 0.82, p = 0.21, treatment 671, control 419, day 28, model 2, propensity score matching, primary outcome, RR approximated with OR.
risk of mechanical ventilation, 6.8% lower, OR 0.93, p = 0.72, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lalau et al., 12/10/2020, retrospective, France, Europe, peer-reviewed, 33 authors, study period 10 March, 2020 - 10 April, 2020.
All Studies   Meta Analysis
This PaperMetforminAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit